Syngene does drug research and manufacturing to order for other pharmaceutical companies — discovery work, development, and manufacturing of both small molecules and biologics — from sites in Bengaluru, Mangaluru, Hyderabad and now Baltimore. Research services were 78% of June-quarter revenue and contract manufacturing 22%. It has been good at it: 8,300 staff including 5,700 scientists, 400 customers, and no listed Indian rival matches its biologics depth. But it is not good at it right now. Revenue fell 16% in the June quarter, the company lost ₹9 crore, and its chairperson says it "drifted towards the larger share of commoditized research services where differentiation is limited."
Not currently. In this business the measures are asset utilisation and pipeline conversion, and management's own word for the first is "improving asset utilisation" — an aim, not an achievement. Mangalore "had a very low utilization in the past years"; the Stelis biologics units hold clinical-stage work but "no large volume commercial molecule from Unit 3"; the Bayview plant in Baltimore is not yet operational and will not be capitalised this year. Syngene does not publish a utilisation percentage. What it has is capacity waiting for customers, which is the opposite of the problem it had two years ago.
No — this is the strongest part of the company. Borrowings were ₹458 crore against ₹4,839 crore of shareholders' funds, a debt-to-equity of 0.09, and down from ₹578 crore a year earlier. Cash of ₹833 crore leaves it ₹375 crore net cash, and management put the June-quarter figure at ₹1,541 crore on a wider definition. Whatever else is going wrong here, the balance sheet is not part of it, and it buys the new management time that a borrowed company would not have.
It is shrinking, and the margin has gone with it. Revenue was ₹736 crore in the June quarter, down 16% on a year earlier, after a full year that grew only 2.6% to ₹3,739 crore. Operating margin fell to 12% in the quarter from 23.6%, and the company reported a loss of ₹9 crore. Management has guided for a single-digit revenue decline across FY27 and margins in the mid-20s — which, with the first quarter at 12%, requires the second half to run near 30%.
Both are going backwards. June-quarter revenue of ₹736 crore was 16% below a year earlier, "primarily reflecting the absence of offtake from Zoetis", with client attrition in research services on top. FY26 revenue rose 2.6% to ₹3,739 crore while profit fell 36% to ₹317 crore. Over three years profit has compounded at −12% a year against revenue growth of 5.4%. The gap between those two numbers is the whole story: the work Syngene kept winning was worth less than the work it was losing.
On its own, and it has been building ahead of demand. Gross block rose 7.1% to ₹3,000 crore last year with a further ₹1,046 crore still in construction, and June-quarter capex was ₹70 crore, mostly the Bayview biologics plant in Baltimore. The capacity was added, in the chairperson's account, "in anticipation of diversifying that business" away from one customer — and then the customer went before the diversification arrived. The spending was not wrong; the sequence was.
Worsening sharply. Operating margin was 12% in the June quarter against 23.6% a year earlier, and 24.6% for FY26 against 28.7% the year before. Roughly ₹50 crore of the quarter's damage was a foreign exchange hedge loss rather than operations, which on ₹736 crore of revenue is about seven percentage points of margin — so the underlying figure was nearer 19%. Cost cutting offset part of it. Neither reading gets close to the mid-20s the company has guided for the full year.
Not any more. Return on capital employed fell to 8.7% from 14.1%, and return on equity to 6.5% from 10.5%. Both figures are held down by capital that is not yet earning — ₹1,046 crore of construction in progress and ₹833 crore of cash sit in the denominator while Bayview waits to open. That is a genuine explanation rather than an excuse, but it only converts into returns if the new capacity fills.
Yes, and this is the number that most contradicts the rest of the page. Operations generated ₹915 crore of cash against ₹317 crore of accounting profit, and over three years cash has run at 2.36 times profit. Customers pay in 50 days, down from 53, and inventory turns in 14 days. A company being squeezed on price is still collecting its money on time — the profit fell because of what it charged, not because of who paid.
Syngene is a Biocon company, and Biocon's founder has taken direct control of it. Kiran Mazumdar-Shaw became executive chairperson from April 2026, and Siddharth Mittal — thirteen years at Biocon, latterly its chief executive — became managing director and CEO on 1 July 2026. He is the third chief executive in eighteen months, after Jonathan Hunt to February 2025 and Peter Bains to June 2026. The board is ten strong with six independent directors and five women. Trust here rests on an unusually frank diagnosis — "we were just being very complacent about one big customer" — from the people who presided over it.
The audit is clean, the tax file is not. B S R & Co. LLP gave an unmodified opinion with one key audit matter — revenue recognition, including bill-and-hold arrangements, flagged for the risk of overstatement. Income tax disputes of ₹518 crore are outstanding across assessment years back to 2008-09, against ₹317 crore of annual profit, and the company expects no material adverse effect. Two smaller matters: the auditor is being replaced by S. R. Batliboi from the 2026 AGM after a full ten-year term, and the company paid a ₹20,000 fine to each exchange for a nine-day lapse in committee composition. US FDA inspections during the year closed with no action or voluntary action indicated.
Syngene sells research to drug companies — 78% of June-quarter revenue — and manufactures for them, 22%. What sets it apart is the biologics end: cell line development through to commercial-scale manufacturing, which, as its CEO puts it, "very few can offer other than if you look at the Chinese and Korean companies." It is also the only Indian peer with a US plant, at Baltimore. The distinguishing capability is real. The distinguishing problem is that most of its revenue still comes from research work its own chairperson calls commoditised.
Divi's Laboratories, Laurus Labs, Anthem Biosciences, Sai Life Sciences, Neuland Laboratories and Piramal Pharma are the listed Indian rivals, with WuXi and Samsung Biologics the global reference points. Syngene's ₹3,739 crore of revenue puts it in the middle of that Indian group — larger than Anthem, Sai Life and Neuland, well behind Divi's at ₹10,560 crore. On margin it now sits at the bottom of the quality half: 24.6% against Anthem's 39.3% and Divi's 32.6%.
Hurting, and it is not subtle: one biologics customer worth "nearly $50 million" has gone, two customers still account for 36% of revenue, research clients are leaving over price, and the June quarter carried a ₹50 crore hedge loss on top. Helping: ₹1,541 crore of net cash, a US plant opening this year, the Biosecure Act pushing work out of China, and a cost programme already visible in the numbers. At ₹401 on 14 August 2026 the share was 51 times last year's earnings — a lot to pay for a repair that management says finishes in FY28.
A long-term grower with a brutal middle. Western drug companies keep outsourcing more, and the Biosecure Act is pushing molecules out of China towards India — that tide is real and Syngene sits on it. But the same industry commoditises anything that can be done cheaply elsewhere, which is precisely what happened to Syngene's discovery work, and single contracts are large enough that losing one takes a fifth of your revenue. The growth is structural; the earnings are not. Both things are true of every company on this list, and Syngene is the one currently proving it.
Syngene is rated more cheaply than any of its listed Indian peers, and it is the only one losing money — and those two facts are the same fact. At 51 times earnings it is rated well below Divi's at 88 or Laurus at 109, but it is being priced against earnings that fell 36% and a quarter that made a loss. The question is not whether the discount is deserved — it is — but whether FY28 looks like management says it will.
Cheap against its peers, expensive against its own earnings. At ₹401 on 14 August 2026 the share was 51 times FY26 earnings of ₹7.86, 3.3 times book value and 4.3 times sales, valuing the company at ₹16,174 crore. Every peer covered here is dearer: Neuland at 82 times, Anthem at 84, Divi's and Sai Life at 88, Laurus at 109. But those companies grew last year. On price to book the gap is starker still — 3.3 times against Divi's 13.4 and Anthem's 16.4 — which is what a market looks like when it doubts the assets will earn their old returns.
Foreign money left, Indian funds took the other side. Foreign institutions fell from 16.5% to 11.8% across the five quarters to June while domestic institutions rose from 24.1% to 28.0% and mutual funds from 20.7% to 25.8% — a near-perfect swap, leaving total institutional ownership almost unchanged at 39.8%. Small shareholders edged up from 6.5% to 7.1% and there are 142,277 of them, no more than a year ago. Read the composition rather than the total: the buyers arriving are index funds, which buy because a rule says so.
Eight holders above 1%, and the list has quietly changed character. In June 2026 the largest were Nippon India at 7.73%, ICICI Prudential's Nifty Smallcap 250 ETF at 5.30%, a DSP Nifty Smallcap 250 index fund at 4.61%, then Government of Singapore at 2.13%, an SBI smallcap index fund, a Mirae healthcare ETF, LIC at 1.78% and HSBC Midcap at 1.55%. A year earlier the same list held actively managed flexi-cap and large-cap funds and two sovereign funds; Government Pension Fund Global has since left it. Smallcap index trackers now hold this stock because of where it sits in an index, not because of a view on it.
Modest on all three. The dividend stays at ₹1.25 a share, ₹50 crore in total and 16% of profit — held flat through a year when profit fell 36%. Share count rose 0.1% to 40.29 crore on employee awards, with a further 7.3 lakh shares approved in April 2026. Borrowings came down from ₹578 crore to ₹458 crore. No money has been raised; with ₹375 crore of net cash and ₹1,046 crore of plant still to finish, none needs to be.
Loading…